EverHint — Stock Analyst Ratings: Upgrades & Downgrades - (Last 24 Hours — November 3, 2025)
(Last 24 Hours — November 3, 2025)
How to read this
- Upgrades / Raises generally reinforce positive sentiment and institutional momentum.
- Downgrades / Cuts can signal valuation compression, risk re-pricing, or post-event profit-taking.
- Price-target changes often track revisions in models after recent earnings or sector updates.
Today’s Key Analyst Moves
- IDEXX Laboratories (IDXX) — Price target raised to $830 from $785 at BTIG, citing continued margin strength and strong diagnostic segment growth.
- Civitas Resources (CIVI) — Downgraded to Peer Perform at Wolfe Research, post-Q3 results suggesting moderation in upstream growth.
- Elevance Health (ELV) — Price target cut to $400 by Mizuho on Carelon headwinds, though the firm maintains Outperform on long-term fundamentals.
- OSI Systems (OSIS) — Target lifted to $320 (from $280) at Oppenheimer following upbeat Q1 beat and raised FY guidance.
- TotalEnergies (TTE) — Price target lowered to $73 by Freedom Capital Markets, reflecting crude softening and currency effects.
- Madison Square Garden Sports (MSGS) — Target trimmed to $268 at Wolfe Research, citing valuation normalization.
- Cigna (CI) — Price target reduced to $350 by Raymond James on pharmacy-benefit margin pressure; long-term view unchanged.
- BioNTech (BNTX) — Price target lowered to $116 by TD Cowen after delays in pivotal oncology trials.
- IDEXX Laboratories (IDXX) — Additional raise: $775 target at Stifel, crediting durable earnings visibility.
- Terns Pharmaceuticals (TERN) — Target raised to $24 by Oppenheimer after promising leukemia drug data.
- Dell Technologies (DELL) — Price target raised to $180 (from $160) at Evercore ISI, citing AI-server demand momentum.
- Amazon (AMZN) — Outperform reiterated at William Blair and Mizuho, highlighting new OpenAI-AWS integration as a growth catalyst.
Vlad’s Take (EverHint)
Analyst revisions this cycle show a rotation toward quality compounders (AMZN, IDXX, DELL) while trimming valuation-rich cyclicals (CIVI, MSGS). Healthcare remains split — Cigna and BioNTech facing idiosyncratic headwinds, while Terns Pharma benefits from data momentum. Overall sentiment leans constructive but selective heading into November’s earnings drift.
Independent, data-driven signals. No hype, no pumps, no paid promotions.